Literature DB >> 15630416

Timeline: Chemotherapy and the war on cancer.

Bruce A Chabner1, Thomas G Roberts.   

Abstract

The era of chemotherapy began in the 1940s with the first uses of nitrogen mustards and antifolate drugs. Cancer drug development since then has transformed from a low-budget, government-supported research effort to a high-stakes, multi-billion dollar industry. The targeted-therapy revolution has arrived, but the principles and limitations of chemotherapy discovered by the early researchers still apply. This article chronicles the history of modern chemotherapy and identifies remaining challenges for the next generation of researchers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15630416     DOI: 10.1038/nrc1529

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  418 in total

1.  Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.

Authors:  Pei-Chih Lee; Rajesh Kakadiya; Tsann-Long Su; Te-Chang Lee
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

2.  Oncology trials--the elephant in the room.

Authors:  Rebecca Kirk; Lisa Hutchinson
Journal:  Nat Rev Clin Oncol       Date:  2012-03-28       Impact factor: 66.675

3.  The Dark Side of the Moon - the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management.

Authors:  Richard Greil
Journal:  Breast Care (Basel)       Date:  2009-06-26       Impact factor: 2.860

4.  Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.

Authors:  Yayun Liang; Cynthia Besch-Williford; Indira Benakanakere; Philip E Thorpe; Salman M Hyder
Journal:  Breast Cancer Res Treat       Date:  2010-03-27       Impact factor: 4.872

Review 5.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

6.  Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.

Authors:  Brian J Park; Zakary L Whichard; Seth J Corey
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

7.  Biodegradable cationic polymeric nanocapsules for overcoming multidrug resistance and enabling drug-gene co-delivery to cancer cells.

Authors:  Chih-Kuang Chen; Wing-Cheung Law; Ravikumar Aalinkeel; Yun Yu; Bindukumar Nair; Jincheng Wu; Supriya Mahajan; Jessica L Reynolds; Yukun Li; Cheng Kee Lai; Emmanuel S Tzanakakis; Stanley A Schwartz; Paras N Prasad; Chong Cheng
Journal:  Nanoscale       Date:  2014       Impact factor: 7.790

Review 8.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Authors:  Himashinie V K Diyabalanage; Michael L Granda; Jacob M Hooker
Journal:  Cancer Lett       Date:  2012-09-29       Impact factor: 8.679

Review 9.  Hedgehog signalling in breast cancer.

Authors:  Maria Kasper; Viljar Jaks; Marie Fiaschi; Rune Toftgård
Journal:  Carcinogenesis       Date:  2009-02-23       Impact factor: 4.944

Review 10.  Targeted nanoparticles for colorectal cancer.

Authors:  Bruno A Cisterna; Nazila Kamaly; Won Il Choi; Ali Tavakkoli; Omid C Farokhzad; Cristian Vilos
Journal:  Nanomedicine (Lond)       Date:  2016-08-16       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.